FDA Inspections Remain Stalled During the COVID-19 Pandemic, Pharmaceutical Technology Magazine

FDA is relying on other global inspection reports and remote document review, yet does not consider them equivalent to on-site inspections. Manufacturers await more clarity.

Mark Schwartz is quoted in this article.